Edition:
United Kingdom

Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

5.05USD
16 Aug 2018
Change (% chg)

$-0.05 (-0.98%)
Prev Close
$5.10
Open
$5.10
Day's High
$5.10
Day's Low
$4.85
Volume
31,821
Avg. Vol
141,735
52-wk High
$8.55
52-wk Low
$2.45

Chart for

About

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related... (more)

Overall

Beta: --
Market Cap(Mil.): $153.67
Shares Outstanding(Mil.): 43.29
Dividend: --
Yield (%): --

Financials

  ADVM.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -1.53 -- --
ROI: -28.12 1.78 14.61
ROE: -29.20 3.28 16.33

BRIEF-Adverum Biotechnologies Reports Q1 Loss Per Share $0.30

* ADVERUM BIOTECHNOLOGIES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

09 May 2018

BRIEF-Adverum Biotechnologies Announces Leadership Changes

* BOARD AND AMBER SALZMAN, CHIEF EXECUTIVE OFFICER MADE A MUTUAL DETERMINATION THAT SALZMAN STEP DOWN

03 May 2018

BRIEF-Adverum Biotechnologies Announces Long-Term Preclinical Efficacy Data On ADVM-022 Gene Therapy In Wet AMD

* ADVERUM BIOTECHNOLOGIES ANNOUNCES LONG-TERM PRECLINICAL EFFICACY DATA ON ADVM-022 GENE THERAPY IN WET AMD

01 May 2018

BRIEF-Adverum Biotechnologies Q4 Loss Per Share $0.32

* ADVERUM BIOTECHNOLOGIES REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

06 Mar 2018

Earnings vs. Estimates